Dr Nat Milton
Nat has an international reputation in the Alzheimer's Drug Discovery and Diagnostics research field. He is a Fellow of the Royal Society of Biology and part of the Biomedical Sciences team in the School of Clinical & Applied Sciences.
For the past 20 years Nat has led the Neuroaptamer research group, which conducts research into identification of target protein binding molecules. The focus of his research has been biochemical interactions of amyloid peptides and their role in Alzheimer's disease, Diabetes, Creutzfeldt-Jakob disease and oxidative stress responses. Nat discovered the neuroprotective actions of cannabinoids in an Alzheimer's disease cell culture model.
He has used aptamer, molecular biology, biochemical and cell biology techniques to discover and characterize the mechanisms of neuroprotection of a number of compounds. He has teaching experience, at both undergraduate and postgraduate levels, in the areas of Physiology, Pharmacology, Clinical Biochemistry, Neuroscience and Entrepreneurship.
Nat is an entrepreneur and has filed a number of patent applications, one of which was granted in the UK and others which were taken to the intention to grant stage in Europe. He has founded an in silico based company, Neurodelta Ltd and raised government funding for commercial research in the Alzheimer’s Drug Discovery and Diagnostic area.
Ask Me About
- Alzheimer's Disease
- Biomedical Sciences
Chilumuri A; Ashioti M; Nercessian AN; Milton NGN (2013), Immunolocalization of kisspeptin associated with amyloid-ß deposits in the pons of an Alzheimer’s disease patient:
Chilumuri A; Milton NGN (2013), The role of neurotransmitters in protection against amyloid-β toxicity by KiSS-1 overexpression in SH-SY5Y neurons: ISRN Neuroendocrinol
Milton NGN (2012), In Vitro Activities of Kissorphin, a Novel Hexapeptide KiSS-1 Derivative, in Neuronal Cells.: